Laboratorio Reig Jofre S A : Reig Jofre submits press release on the results of the first quarter of 2024
May 10, 2024 at 03:24 am EDT
Share
Reig Jofre submits press release on the results of the first quarter of 2024
9 May 2024
REIG JOFRE's revenues grow 10% and its EBITDA rises 11% in the first quarter
REIG JOFRE exceeded 86 million euros in sales, 10% higher than the first quarter of 2023. Profitability was also improved, with EBITDA growing by 11% to 10.3 million euros, compared to 9.2 million euros at the close of the same period of the previous year.
The Speciality Pharmacare division, focused on prescription medical products, achieved the highest revenue growth of +26%. The division with the greatest weight in sales, Pharmaceutical Technologies, dedicated to injectable products and antibiotics, achieved a growth of 6%, followed by Consumer Healthcare, the consumer products division, which contributes 24% of the group's sales, with FORTÉ PHARMA brand, in the French, Belgian and Spanish markets, and REIG JOFRE OTC products.
Download the full document (PDF)
Attachments
Original Link
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on
09 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
10 May 2024 07:23:01 UTC.
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
